UnitedHealth Group Inc. (NYSE: UNH) is one of the best-selling S&P 500 shares to date in 2025. Stocks had fallen slightly in 2024, but in 2025 it fell sharply, reaching the top three sales inventory. The recession began primarily with a weak quarterly outcome and revisions to guidance in April 2025, further exacerbated by the CEO’s resignation and the suspension of guidance in May.
As the company approaches its second quarter 2025 revenue results, its guidance and management growth plans are undergoing new scrutiny. On July 9, Barclays analyst Andrew Mok revised the company’s price targets, lowering the company’s second quarter revenue release, scheduled for July 29, from $350 to $337 first. Despite adjustments, he maintained the stock’s purchase rating.
While receiving healthcare services at the clinic, older Medicare-friendly consumers will be happy to smile.
The decline in targets reflects a reduction in MOK’s earnings per share forecast for 2026. He has not changed his positive view of the company’s long-term potential, but the revisions suggest a more cautious attitude towards revenue prospects for the coming years.
In a similar move, Wolf research analyst Justin Lake reduced the stock’s price target from $363 to $330 on July 10.
UnitedHealth Group Inc. (NYSE: UNH) is a healthcare company providing health insurance and medical solutions in the United States and around the world under the UnitedHealthCare and Optum brands.
Although we acknowledge the potential of UNH as an investment, we believe certain AI stocks offer greater promotion potential and pose a risk of decline. If you’re looking for a highly underrated AI stock that can make a significant profit from the tariff and supervision trends of the Trump era, check out our free report on the best short-term AI stocks.
Read next: Harvard University Stock Portfolio: Top 10 Stock Picks and 20 Undervalued Momentum Stocks are taking off.
Disclosure: None. This article was originally published on Insider Monkey.
